Importance of subtype selectivity for endothelin receptor antagonists in the human vasculature

Translational Vascular Medicine: Pathogenesis, Diagnosis, and Treatment

Volumn 9781430236870, Issue , 2012, Pages 151-172

  Maguire, Janet J ^a   Davenport, Anthony P ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84949180136     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-0-85729-920-8_10     Document Type: Chapter

References (104)

1. Yanagisawa M, Kurihara H, Kimura S, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 1988;332:411-5.
2. Inoue A, Yanagisawa M, Kimura S, et al. The human endothelin family: Three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc Natl Acad Sci USA. 1989;86:2863-7.
3. Hosoda K, Nakao K, Tamura N, et al. Organization, structure, chromosomal assignment, and expression of the gene encoding the human endothelin-A receptor. J Biol Chem. 1992;267: 18797-804.
4. Arai H, Hori S, Aramori I, Ohkubo H, Nakanishi S. Cloning and expression of a cDNA encoding an endothelin receptor. Nature. 1990;348:730-2.
5. Sakurai T, Yanagisawa M, Takuwa Y, et al. Cloning of a cDNA encoding a non-isopeptideselective subtype of the endothelin receptor. Nature. 1990;348:732-5.
6. Davenport AP. International Union of Pharmacology. XXIX. Update on endothelin receptor nomenclature. Pharmacol Rev. 2002;54:219-26.
7. Davenport AP, Maguire JJ. Endothelin. Handb Exp Pharmacol. 2006;176(Pt 1):295-329.
8. Palmer MJ. Endothelin receptor antagonists: Status and learning 20 years on. Prog Med Chem. 2009;47:203-37.
9. Xu D, Emoto N, Giaid A, et al. ECE-1: A membrane-bound metalloprotease that catalyzes the proteolytic activation of big endothelin-1. Cell. 1994;78:473-85.
10. Emoto N, Yanagisawa M. Endothelin-converting enzyme-2 is a membrane-bound, phosphoramidon- Sensitive metalloprotease with acidic pH optimum. J Biol Chem. 1995;270:15262-8.
11. Russell FD, Davenport AP. Secretory pathways in endothelin synthesis. Br J Pharmacol. 1999;126:391-8.
12. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med. 2002;346:896-903.
13. Vatter H, Seifert V. Ambrisentan, a non-peptide endothelin receptor antagonist. Cardiovasc Drug Rev. 2006;24:63-76.
14. Galie N, Naeije R, Burgess G, Dilleen M. 3-year survival of patients treated with sitaxentan sodium (Thelin®) for pulmonary arterial hypertension. European Society of Cardiology, Barcelona, Spain; August 29-September 2, 2009.
15. Benza RL, Mehta S, Keogh A, et al. Sitaxsentan treatment for patients with pulmonary arterial hypertension discontinuing bosentan. J Heart Lung Transplant. 2007;26:63-6.
16. Liu C, Chen J, Gao Y, Deng B, Liu K. Endothelin receptor antagonists for pulmonary arterial hypertension. Cochrane Database Syst Rev. 2009;3:CD004434.
17. McLaughlin VV, Archer SL, Badesch DB, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: A report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: Developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association. Circulation. 2009;119:2250-94.
18. Dupuis J, Hoeper MM. Endothelin receptor antagonists in pulmonary arterial hypertension. Eur Respir J. 2008;31:407-15.
19. Vachiery J-L, Davenport AP. The endothelin system in pulmonary and renal asculopathy - "Les liaisons dangereuses". Eur Respir Rev. 2009;18:260-1.
20. Davie NJ, Schermuly RT, Weissmann N, Grimminger F, Ghofrani HA. The science of endothelin- 1 and endothelin receptor antagonists in the management of pulmonary arterial hypertension: current understanding and future studies. Eur J Clin Invest. 2009;39 Suppl 2:38-49.
21. Dhaun N, Pollock DM, Goddard J, Webb DJ. Selective and mixed endothelin receptor antagonism in cardiovascular disease. Trends Pharmacol Sci. 2007;28:573-9.
22. Kohan DE. Endothelins in the normal and diseased kidney. Am J Kidney Dis. 1997;29:2-26.
23. Karet FE, Davenport AP. Localization of endothelin peptides in human kidney. Kidney Int. 1996;49:382-7.
24. Karet FE, Kuc RE, Davenport AP. Novel ligands BQ123 and BQ3020 characterize endothelin receptor subtypes ETA and ETB in human kidney. Kidney Int. 1993;44:36-42.
25. Kohan DE. Endothelin, hypertension and chronic kidney disease: New insights. Curr Opin Nephrol Hypertens. 2010;19:134-9.
26. Longaretti L, Benigni A. Endothelin receptor selectivity in chronic renal failure. Eur J Clin Invest. 2009;39 Suppl 2:32-7.
27. Neuhofer W, Pittrow D. Endothelin receptor selectivity in chronic kidney disease: Rationale and review of recent evidence. Eur J Clin Invest. 2009;39 Suppl 2:50-67.
28. Goddard J, Johnston NR, Hand MF, et al. Endothelin-A receptor antagonism reduces blood pressure and increases renal blood flow in hypertensive patients with chronic renal failure: A comparison of selective and combined endothelin receptor blockade. Circulation. 2004;109: 1186-93.
29. Abraham D, Dashwood M. Endothelin-role in vascular disease. Rheumatology (Oxford). 2008;47 Suppl 5:23-4.
30. Bhalla A, Haque S, Taylor I, Winslet M, Loizidou M. Endothelin receptor antagonism and cancer. Eur J Clin Invest. 2009;39 Suppl 2:74-7.
31. Bagnato A, Spinella F, Rosano L. The endothelin axis in cancer: The promise and the challenges of molecularly targeted therapy. Can J Physiol Pharmacol. 2008;86:473-84.
32. Growcott JW. Preclinical anticancer activity of the specific endothelin A receptor antagonist ZD4054. Anticancer Drugs. 2009;20:83-8.
33. Dickstein K, De Voogd HJ, Miric MP, et al. Effect of single doses of SLV306, an inhibitor of both neutral endopeptidase and endothelin-converting enzyme, on pulmonary pressures in congestive heart failure. Am J Cardiol. 2004;94:237-9.
34. Bayes M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2003;25:317-40.
35. Tabrizchi R. SLV-306. Solvay. Curr Opin Investig Drugs. 2003;4:329-32.
36. Russell FD, Skepper JN, Davenport AP. Human endothelial cell storage granules: A novel intracellular site for isoforms of the endothelin-converting enzyme. Circ Res. 1998;83:314-21.
37. Maguire JJ, Davenport AP. ETA receptor-mediated constrictor responses to endothelin peptides in human blood vessels in vitro. Br J Pharmacol. 1995;115:191-7.
38. Davenport AP, Maguire JJ. Is endothelin-induced vasoconstriction mediated only by ETA receptors in humans? Trends Pharmacol Sci. 1994;15:9-11.
39. Haynes WG, Webb DJ. Contribution of endogenous generation of endothelin-1 to basal vascular tone. Lancet. 1994;344:852-4.
40. Love MP, Ferro CJ, Haynes WG, et al. Endothelin receptor antagonism in patients with chronic heart failure. Cardiovasc Res. 2000;47:166-72.
41. Kiowski W, Luscher TF, Linder L, Buhler FR. Endothelin-1-induced vasoconstriction in humans. Reversal by calcium channel blockade but not by nitrovasodilators or endotheliumderived relaxing factor. Circulation. 1991;83:469-75.
42. Kurihara Y, Kurihara H, Suzuki H, et al. Elevated blood pressure and craniofacial abnormalities in mice deficient in endothelin-1. Nature. 1994;368:703-10.
43. Fukuroda T, Fujikawa T, Ozaki S, et al. Clearance of circulating endothelin-1 by ETB receptors in rats. Biochem Biophys Res Commun. 1994;199:1461-5.
44. Gasic S, Wagner OF, Vierhapper H, Nowotny P, Waldhausl W. Regional hemodynamic effects and clearance of endothelin-1 in humans: Renal and peripheral tissues may contribute to the overall disposal of the peptide. J Cardiovasc Pharmacol. 1992;19:176-80.
45. Plumpton C, Ferro CJ, Haynes WG, Webb DJ, Davenport AP. The increase in human plasma immunoreactive endothelin but not big endothelin-1 or its C-terminal fragment induced by systemic administration of the endothelin antagonist TAK-044. Br J Pharmacol. 1996;119:311-4.
46. Davenport AP, Russell FD. Endothelin converting enzymes and endothelin receptor localisation in human tissues. Handb Exp Pharmacol. 2001;152:209-37.
47. Kuc RE, Karet FE, Davenport AP. Characterization of peptide and nonpeptide antagonists in human kidney. J Cardiovasc Pharmacol. 1995;26 Suppl 3:S373-5.
48. Gariepy CE, Ohuchi T, Williams SC, Richardson JA, Yanagisawa M. Salt-sensitive hypertension in endothelin-B receptor-deficient rats. J Clin Invest. 2000;105:925-33.
49. Gandhi CR, Stephenson K, Olson MS. Endothelin, a potent peptide agonist in the liver. J Biol Chem. 1990;265:17432-5.
50. Pitts KR. Endothelin receptor antagonism in portal hypertension. Expert Opin Investig Drugs. 2009;18:135-42.
51. Rockey DC, Weisiger RA. Endothelin induced contractility of stellate cells from normal and cirrhotic rat liver: Implications for regulation of portal pressure and resistance. Hepatology. 1996;241:233-40.
52. Hinterhuber L, Graziadei IW, Kahler CM, Jaschke W, Vogel W. Endothelin-receptor antagonist treatment of portopulmonary hypertension. Clin Gastroenterol Hepatol. 2004;2:1039-42.
53. Reichen J, Gerbes AL, Steiner MJ, Sagesser H, Clozel M. The effect of endothelin and its antagonist Bosentan on hemodynamics and microvascular exchange in cirrhotic rat liver. J Hepatol. 1998;28:1020-30.
54. Kojima H, Yamao J, Tsujimoto T, Uemura M, Takaya A, Fukui H. Mixed endothelin receptor antagonist, SB209670, decreases portal pressure in biliary cirrhotic rats in vivo by reducing portal venous system resistance. J Hepatol. 2000;32:43-50.
55. Feng HQ, Weymouth ND, Rockey DC. Endothelin antagonism in portal hypertensive mice: Implications for endothelin receptor-specific signaling in liver disease. Am J Physiol Gastrointest Liver Physiol. 2009;297:G27-33.
56. Johnstrom P, Harris NG, Fryer TD, et al. [ 18 F]-Endothelin-1, a positron emission tomography (PET) radioligand for the endothelin receptor system: Radiosynthesis and in vivo imaging using microPET. Clin Sci. 2002;103 Suppl 48:4S-8.
57. Kelland NF, Kuc RE, McLean DL, et al. Endothelial cell-specific ETB receptor knockout: Autoradiographic and histological characterisation and crucial role in the clearance of endothelin- 1. Can J Physiol Pharmacol. 2010;88:644-51.
58. Bagnall AJ, Kelland NF, Gulliver-Sloan F, et al. Deletion of endothelial cell endothelin B receptors does not affect blood pressure or sensitivity to salt. Hypertension. 2006;48:286-93.
59. Maguire JJ, Johnson CM, Mockridge JW, Davenport AP. Endothelin converting enzyme (ECE) activity in human vascular smooth muscle. Br J Pharmacol. 1997;122:1647-54.
60. Maguire JJ, Davenport AP. Increased response to big endothelin-1 in atherosclerotic human coronary artery: functional evidence for up-regulation of endothelin-converting enzyme activity in disease. Br J Pharmacol. 1998;125:238-40.
61. Dive V, Chang CF, Yiotakis A, Sturrock ED. Inhibition of zinc metallopeptidases in cardiovascular disease-from unity to trinity, or duality? Curr Pharm Des. 2009;15:3606-21.
62. Battistini B, Daull P, Jeng AY. CGS 35601, a triple inhibitor of angiotensin converting enzyme, neutral endopeptidase and endothelin converting enzyme. Cardiovasc Drug Rev. 2005;23: 317-30.
63. Kuc RE, Ashby MJ, Seed A, et al. The ECE/NEP inhibitor SLV306 (Daglutril), inhibits systemic endogenous conversion of infused big endothelin-1 in human volunteers. Proc Br Pharmacol Soc. 2005. doi: Http://www.pA2online.org/abstracts/Vol3Issue4abst029P.pdf.
64. Johnstrom P, Fryer TD, Richards HK, et al. Positron emission tomography of [18F]-big endothelin-1 reveals renal excretion but tissue-specific conversion to [18F]-endothelin-1 in lung and liver. Br J Pharmacol. 2010;159:812-9.
65. Naruse K, Naruse M, Watanabe Y, et al. Molecular form of immunoreactive endothelin in plasma and urine of normal subjects and patients with various disease states. J Cardiovasc Pharmacol. 1991;17 Suppl 7:S506-8.
66. Yanagisawa H, Hammer RE, Richardson JA, et al. Disruption of ECE-1 and ECE-2 reveals a role for endothelin-converting enzyme-2 in murine cardiac development. J Clin Invest. 2000;105:1373-82.
67. D'Orleans-Juste P, Houde M, Rae GA, Bkaily G, Carrier E, Simard E. Endothelin-1 (1-31): from chymase-dependent synthesis to cardiovascular pathologies. Vasc Pharmacol. 2008;49:51-62.
68. Fecteau MH, Honore JC, Plante M, Labonte J, Rae GA, D'Orleans-Juste P. Endothelin-1 (1-31) is an intermediate in the production of endothelin-1 after big endothelin-1 administration in vivo. Hypertension. 2005;46:87-92.
69. Maguire JJ, Kuc RE, Davenport AP. Vasoconstrictor activity of novel endothelin peptide, ET-1(1-31), in human mammary and coronary arteries in vitro. Br J Pharmacol. 2001;134: 1360-6.
70. O'Reilly G, Charnock-Jones DS, Morrison JJ, Cameron IT, Davenport AP, Smith SK. Alternatively spliced mRNAs for human endothelin-2 and their tissue distribution. Biochem Biophys Res Commun. 1993;193:834-40.
71. Plumpton C, Ashby MJ, Kuc RE, O'Reilly G, Davenport AP. Expression of endothelin peptides and mRNA in the human heart. Clin Sci. 1996;90(1):37-46.
72. Howard PG, Plumpton C, Davenport AP. Anatomical localization and pharmacological activity of mature endothelins and their precursors in human vascular tissue. J Hypertens. 1992;10:1379-86.
73. Matsumoto H, Suzuki N, Kitada C, Fujino M. Endothelin family peptides in human plasma and urine: Their molecular forms and concentrations. Peptides. 1994;15:505-10.
74. Bacon CR, Davenport AP. Endothelin receptors in human coronary artery and aorta. Br J Pharmacol. 1996;117:986-92.
75. Chang I, Bramall, A, Baynash AG et al. Genetic study of ET-2 in mice. Eleventh international conference on endothelin, Montréal; 2009. p. 15.
76. Marciniak SJ, Plumpton C, Barker PJ, et al. Localization of immunoreactive endothelin and proendothelin in the human lung. Pulm Pharmacol. 1992;5:175-82.
77. Davenport AP, Hoskins SL, Kuc RE, Plumpton C. Differential distribution of endothelin peptides and receptors in human adrenal gland. Histochem J. 1996;28:779-89.
78. Davenport AP, Kuc RE, Mockridge JW. Endothelin-converting enzyme in the human vasculature: evidence for differential conversion of big endothelin-3 by endothelial and smooth-muscle cells. J Cardiovasc Pharmacol. 1998;31 Suppl 1:S1-3.
79. Maguire JJ, Davenport AP. No alteration in vasoconstrictor endothelin-B-receptor density or function in human coronary artery disease. J Cardiovasc Pharmacol. 2000;36(5 Suppl 1):S380-1.
80. Halcox JP, Nour KR, Zalos G, Quyyumi AA. Endogenous endothelin in human coronary vascular function: Differential contribution of endothelin receptor types A and B. Hypertension. 2007;49:1134-41.
81. McCulloch KM, Docherty CC, Morecroft I, MacLean MR. EndothelinB receptor-mediated contraction in human pulmonary resistance arteries. Br J Pharmacol. 1996;119:1125-30.
82. Davie N, Haleen SJ, Upton PD, et al. ET(A) and ET(B) receptors modulate the proliferation of human pulmonary artery smooth muscle cells. Am J Respir Crit Care Med. 2002;165:398-405.
83. Davenport AP, Kuc RE. Radioligand binding and molecular imaging techniques for the quantitative analysis of established and emerging orphan receptors systems. Methods Mol Biol. 2005;306:93-120.
84. Wu-Wong JR, Chiou WJ, Hoffman DJ, et al. Endothelins and endothelin receptor antagonists: binding to plasma proteins. Life Sci. 1996;58:1839-47.
85. Williams Jr DL, Jones KL, Alves K, Chan CP, Hollis GF, Tung JS. Characterization of cloned human endothelin receptors. Life Sci. 1993;53:407-14.
86. Molenaar P, O'Reilly G, Sharkey A, et al. Characterization and localization of endothelin receptor subtypes in the human atrioventricular conducting system and myocardium. Circ Res. 1993;72:526-38.
87. Aramori I, Nirei H, Shoubo M, et al. Subtype selectivity of a novel endothelin antagonist, FR139317, for the two endothelin receptors in transfected Chinese hamster ovary cells. Mol Pharmacol. 1993;43:127-31.
88. Peter MG, Davenport AP. Characterization of the endothelin receptor selective agonist, BQ3020 and antagonists BQ123, FR139317, BQ788, 50235, Ro462005 and bosentan in the heart. Br J Pharmacol. 1996;117:455-62.
89. Peter MG, Davenport AP. Selectivity of [125I]-PD151242 for human, rat and porcine endothelin ETA receptors in the heart. Br J Pharmacol. 1995;114:297-302.
90. Doherty AM, Cody WL, He JX, et al. In vitro and in vivo studies with a series of hexapeptide endothelin antagonists. J Cardiovasc Pharmacol. 1993;22 Suppl 8:S98-102.
91. Breu V, Loffl er BM, Clozel M. In vitro characterization of Ro 46-2005, a novel synthetic nonpeptide endothelin antagonist of ETA and ETB receptors. FEBS Lett. 1993;334:210-4.
92. Clozel M, Breu V, Gray GA, et al. Pharmacological characterization of bosentan, a new potent orally active nonpeptide endothelin receptor antagonist. J Pharmacol Exp Ther. 1994;270: 228-35.
93. Wu C, Chan MF, Stavros F, et al. Discovery of TBC11251, a potent, long acting, orally active endothelin receptor-A selective antagonist. J Med Chem. 1997;40:1690-7.
94. Webb ML, Bird JE, Liu EC, et al. BMS-182874 is a selective, nonpeptide endothelin ETA receptor antagonist. J Pharmacol Exp Ther. 1995;272:1124-34.
95. Elliott JD, Lago MA, Cousins RD, et al. 1, 3-Diarylindan-2-carboxylic acids, potent and selective non-peptide endothelin receptor antagonists. J Med Chem. 1994;37:1553-7.
96. Johnstrom P, Fryer TD, Richards HK, et al. In vivo imaging of cardiovascular endothelin receptors using the novel radiolabelled antagonist [18F]-SB209670 and positron emission tomography (microPET). J Cardiovasc Pharmacol. 2004;44 Suppl 1:S34-8.
97. Patt WC, Edmunds JJ, Repine JT, et al. Structure-activity relationships in a series of orally active gamma-hydroxy butenolide endothelin antagonists. J Med Chem. 1997;40:1063-74.
98. Maguire JJ, Kuc RE, Davenport AP. Affinity and selectivity of PD156707, a novel nonpeptide endothelin antagonist, for human ET(A) and ET(B) receptors. J Pharmacol Exp Ther. 1997;280:1102-8.
99. Walsh TF, Fitch KJ, Chakravarty PK, et al. The discovery of L-749329, a highly potent, orally active antagonist of endothelin receptors. Abstr Pap Am Chem Soc. 1994;298:145.
100. Fujimoto M, Mihara S, Nakajima S, Ueda M, Nakamura M, Sakurai K. A novel non-peptide endothelin antagonist isolated from bayberry, Myrica cerifera. FEBS Lett. 1992;305:41-4.
101. Mihara S, Nakajima S, Matumura S, Kohnoike T, Fujimoto M. Pharmacological characterization of a potent nonpeptide endothelin receptor antagonist, 97-139. J Pharmacol Exp Ther. 1994;268(3):1122-8.
102. Davenport AP, O'Reilly G, Kuc RE. Endothelin ETA and ETB mRNA and receptors expressed by smooth muscle in the human vasculature: Majority of the ETA sub-type. Br J Pharmacol. 1995;114:1110-6.
103. Davenport AP, Kuc RE, Fitzgerald F, Maguire JJ, Berryman K, Doherty AM. [125I]- PD151242: A selective radioligand for human ETA receptors. Br J Pharmacol. 1994;111: 4-6.
104. Maguire JJ, Bacon CR, Fujimoto M, Davenport AP. Myricerone caffeoyl ester (50-235) is a non-peptide antagonist selective for human ETA receptors. J Hypertens. 1994;12(6): 675-80.